ITOS director’s in-the-money options converted to cash and contingent rights
Rhea-AI Filing Summary
iTeos Therapeutics insider option cancellations tied to merger consideration. The reporting person, a director, disposed of stock options as part of a merger that converted certain in-the-money options into cash and contingent value rights. Options with exercise prices of $2.95 (25,140 options) and $4.24 (146,160 options) were canceled because their exercise prices were below the merger cash consideration of $10.047 per share. Holders of those canceled options are entitled to receive a cash payment equal to the excess of the cash consideration over each option's exercise price multiplied by the number of underlying shares, plus one non-transferable contractual contingent value right per underlying share. The Form 4 reports these changes in beneficial ownership resulting from the merger terms.
Positive
- Conversion to cash for in-the-money options provides immediate, quantifiable value to option holders.
- Clear disclosure of exercise prices ($2.95 and $4.24), number of options (25,140 and 146,160), and merger cash per share ($10.047).
Negative
- Loss of future equity upside for option holders due to cancellation of options in exchange for cash and non-transferable contingent rights.
- Contingent value rights are non-transferable, limiting liquidity and marketability of that portion of consideration.
Insights
TL;DR: Merger resulted in cash-out of in-the-money options and issuance of contingent value rights, crystallizing value for option holders.
The cancellation of options with exercise prices materially below the merger cash consideration converts latent option value into immediate cash entitlements and contingent value rights. For the reported options, the per-option cash payout equals the difference between $10.047 and the respective exercise prices, multiplied by 171,300 aggregate underlying shares. This is a standard merger adjustment that eliminates upside tied to the standalone equity while providing secured cash consideration plus contingent rights tied to post-closing events. For holders, this removes future exposure to stock performance in exchange for defined cash value and contractual contingent claims.
TL;DR: The transaction follows typical merger mechanics; disclosure shows compliance with merger agreement terms.
The Form 4 discloses that in-the-money options were canceled and converted per the Merger Agreement, with affected optionholders receiving cash and contingent value rights. The reporting person is identified as a director and the filing is made under Section 16 changes in beneficial ownership. The submission includes necessary explanatory footnotes describing the computation of cash consideration and the issuance of non-transferable contingent value rights, reflecting customary governance and disclosure practices in a cash-out merger.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) | 25,140 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 146,160 | $0.00 | -- |
Footnotes (1)
- This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the "Company"), Concentra Biosciences LLC ("Parent"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Parent completed a tender offer for shares of common stock of the Company ("Shares") and thereafter, the Merger Sub merged with and into the Company (the "Merger"). In accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company that had an exercise price per share that is less than the $10.047 in cash per share (the "Cash Amount") (each, an "In-the-Money Option") that was then outstanding was canceled and, in exchange therefor, (Continued from footnote 1) the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one non-transferable contractual contingent value right for each Share underlying such In-the-Money Option.
